Compare Johnson & Johnson (JNJ) vs Nvidia Corp (NVDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Nvidia Corp — how do they compare? Johnson & Johnson trades at $260.45 (market cap $618.09B), while Nvidia Corp trades at $229.6 (market cap $5.57T). The key difference: Nvidia Corp is far larger — about 9× Johnson & Johnson's market cap, and Johnson & Johnson pays the higher dividend (2.09%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Nvidia Corp for 115 Days on average.
| JNJ | NVDA | |
|---|---|---|
Market Cap | $618.09B | $5.57T |
Volume | 6,050,983 | 117,720,595 |
Sector | Health | Technology |
52-Week High | $278.43 | $239.27 |
52-Week Low | $186.00 | $165.17 |
Typical Hold Time | 129 Days | 115 Days |
Enterprise Value | $646.37B | $5.54T |
Dividend Yield | 2.09% | 0.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
NVIDIA (NVDA) trades at $229.25, down 3.42% over the past day amid a broader tech sell-off. The stock maintains a bullish technical signal with strong support near $228 and resistance at $235. Fundamentally, the company reported record revenue of $130.50B in 2025, with net income surging to $72.88B, reflecting a 55.84% profit margin. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.22 surpassing the $2.09 estimate. Analyst sentiment remains overwhelmingly positive, with a consensus price target of $339.17 implying significant upside.
NVDA's outlook is supported by robust AI chip demand and accelerating revenue growth, projected to reach $303.0B in 2026. However, risks include heightened competition, potential peak AI spending, and geopolitical tensions affecting market sentiment. The stock presents a compelling growth opportunity but requires monitoring of execution risks and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →
